SCHEMBL4592789

SCHEMBL4592789

CC(=O)NCC1CCN(Cc2ccc(Br)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 5/20 0.54
HDAC4 P56524 5/20 0.54
HDAC1 Q13547 5/20 0.54
HDAC7 Q8WUI4 5/20 0.54
HDAC2 Q92769 5/20 0.54
HDAC10 Q969S8 5/20 0.54
HDAC11 Q96DB2 5/20 0.54
HDAC8 Q9BY41 5/20 0.54
HDAC6 Q9UBN7 5/20 0.54
HDAC9 Q9UKV0 5/20 0.54
HDAC5 Q9UQL6 5/20 0.54
ACHE P22303 4/20 0.54
KCNH2 Q12809 2/20 0.54
CACNA1I Q9P0X4 2/20 0.54
FAAH O00519 2/20 0.53
BCHE P06276 2/20 0.53
CCR3 P51677 1/20 0.53
LTA4H P09960 1/20 0.53
SIGMAR1 Q99720 1/20 0.52
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27558611 0.88 CCR2 (0.62) ACHEKCNH2CACNA1IFAAHBCHE
SCHEMBL17469031 0.86 ACHE (0.70) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4591230 0.85 CCR3 (0.57) BCHECCR3ALDH1A1
SCHEMBL4592089 0.81 SIGMAR1 (0.68) KCNH2LTA4HSIGMAR1KDM4EALDH1A1
SCHEMBL9046417 0.78 ACHE (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5700590 0.78 CCR5 (0.77)
SCHEMBL3946020 0.77 ACHE (0.62) ACHEBCHE
SCHEMBL4592032 0.77 ACHE (0.58) ACHESIGMAR1KDM4EALDH1A1CHRM2
SCHEMBL31540760 0.77 CACNA1I (0.58) ACHEKCNH2CACNA1ICCR3
SCHEMBL4592063 0.76 ALDH1A1 (0.54) ACHEFAAHBCHECCR3LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101296906-A (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INT (DE) 2008-10-29 CN disclosed
EP-1943231-A1 (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-16 EP disclosed
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds ROTH GERALD J 2007-05-17 US disclosed
WO-2007048802-A1 (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 HDAC3 796/4885HDAC4 1950/4885HDAC1 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.